Evaluation of the response to ranibizumab therapy following bevacizumab treatment failure in eyes with diabetic macular edema

Case Reports in Ophthalmology

Volumn 6, Issue 1, 2015, Pages 44-50

  Hanhart, Joel ^a,b   Chowers, Itay ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Bevacizumab; Diabetic macular edema; Ranibizumab; Treatment failure

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RETINAL THICKNESS; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84929581853     PISSN: None     EISSN: 16632699     Source Type: Journal    
DOI: 10.1159/000375230     Document Type: Article

References (29)

1. Yau JW, Rogers SL, Kawasaki R, et al: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564.
2. Aiello LP, Bursell SE, Clermont A, et al: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
3. Mitchell P, Wong TY; Diabetic Macular Edema Treatment Guideline Working Group: Management paradigms for diabetic macular edema. Am J Ophthalmol 2014;157:505-513.
4. Elman MJ, Qin H, Aiello LP, et al: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-2318.
5. Lang GE, Berta A, Eldem BM, et al: Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the restore extension study. Ophthalmology 2013;120:2004-2012.
6. Martin DF, Maguire MG, Fine SL, et al: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
7. Massin P, Bandello F, Garweg JG, et al: Safety and efficacy of ranibizumab in diabetic macular edema (resolve study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:2399-2405.
8. Brown DM, Nguyen QD, Marcus DM, et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
9. Nguyen QD, Shah SM, Khwaja AA, et al: Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-2151.
10. Arevalo JF, Lasave AF, Wu L, et al: Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the pan-american collaborative retina study group at 24 months. Retina 2013;33:403-413.
11. Sivaprasad S, Crosby-Nwaobi R, Heng LZ, et al: Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (bolt report 5). Br J Ophthalmol 2013;97:1177-1180.
12. Stefanini FR, Arevalo JF, Maia M: Bevacizumab for the management of diabetic macular edema. World J Diabetes 2013;4:19-26.
13. Aiello LP, Beck RW, Bressler NM, et al: Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 2011;118:e5-e14.
14. Beck RW, Edwards AR, Aiello LP, et al: Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
15. Brown DM, Kaiser PK, Michels M, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
16. Rosenfeld PJ, Brown DM, Heier JS, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
17. Gasperini JL, Fawzi AA, Khondkaryan A, et al: Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20.
18. Kaiser RS, Gupta OP, Regillo CD, et al: Ranibizumab for eyes previously treated with pegaptanib or bevacizumab without clinical response. Ophthalmic Surg Lasers Imaging 2012;43:13-19.
19. Kent JS, Iordanous Y, Mao A, et al: Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Can J Ophthalmol 2012;47:159-164.
20. Otsuji T, Nagai Y, Sho K, et al: Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol 2013;7:1487-1490.
21. Tranos P, Vacalis A, Asteriadis S, et al: Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther 2013;7:485-490.
22. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al: A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013;156:502-510 e502.
23. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S: Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther 2011;27:373-377.
24. Kühn T: Results of an expert survey on VEGF inhibitors in ophthalmology (in German). Klin Monbl Augenheilkd 2011;228:607-612.
25. Eghoj MS, Sorensen TL: Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2012;96:21-23.
26. Chong V: Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Ophthalmologica 2012;227(suppl 1):2-10.
27. Labriola LT, Sadda SR: Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. Semin Ophthalmol 2011;26:387-391.
28. Binder S: Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 2012;96:1-2.
29. Ehlken C, Jungmann S, Böhringer D, et al: Switch of anti-VEGF is an option for nonresponders in the treatment of AMD. Eye (London) 2014;28:538-545.